List of Wegovy drug patents
Wegovy is owned by Novo.
Wegovy contains Semaglutide.
Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.
Wegovy was authorised for market use on 04 June, 2021.
Wegovy is available in solution;subcutaneous dosage forms.
Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.
Drug patent challenges can be filed against Wegovy from December, 2021.
The generics of Wegovy are possible to be released after 17 February, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(3 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(15 years from now) | |
| US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
| New Product (NP) | Jun 4, 2024 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic